THE VALUE OF LOOKING BEYOND OVERALL SURVIVAL: THE ROLE OF ONCOLOGY-RELEVANT ENDPOINTS IN HTA / PAYER DECISION-MAKING

被引：0

作者：

Fameli, A. ^{[1
]}

Fernandez, C. ^{[2
]}

Krueger, T. ^{[3
]}

Podkonjak, T. ^{[4
]}

Cattaneo, I ^{[5
]}

Rotaru, M. ^{[6
]}

Ryan, J. ^{[7
]}

McLaughlan, B. ^{[8
]}

Marques, S. ^{[9
]}

Calzada, V ^{[10
]}

Carreras, M. ^{[11
]}

Sapede, C. ^{[12
]}

Gross-Langenhoff, M. ^{[13
]}

Caic, F. ^{[14
]}

机构：

[1] GSK London, London, England

[2] Sanofi, Gentilly, France

[3] MSD, Luzern, Switzerland

[4] Takeda Pharmaceut Int AG, Zurich, Switzerland

[5] Novartis Farma SpA, Origgio, VA, Italy

[6] European Federat Pharmaceut Ind & Associat, Brussels, Belgium

[7] AstraZeneca, Cambridge, England

[8] Astellas Pharma Europe, Surrey, England

[9] AstraZeneca, Zug, Switzerland

[10] Sanofi, Paris, France

[11] F Hoffmann La Roche Ltd, Basel, Switzerland

[12] Novartis, Basel, Switzerland

[13] Astellas Pharma Europe, Munich, Germany

[14] Merck Grp, Brussels, Belgium

来源：

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

HTA6

引用

页码：S321 / S321

页数：1